StockData
ANRONYSEPharmaceutical PreparationsFiscal year ends December 31

Alto Neuroscience, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$22.82+0.88 (+4.01%)

Close on Oct 19, 2026

Market cap
$976.99M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 12, 2026After market close–$-0.65–
Q1 FY2026
Ended Mar 31, 2026
May 13, 2026Before market open–$-0.80–
Q4 FY2025
Ended Dec 31, 2025
Mar 16, 2026Before market open–––
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025Before market open–$-0.52–
Q2 FY2025
Ended Jun 30, 2025
Aug 13, 2025After market close–––
Q1 FY2025
Ended Mar 31, 2025
May 14, 2025After market close–$-0.56–
Q4 FY2024
Ended Dec 31, 2024
Mar 20, 2025After market close–––
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024After market close–––
Q2 FY2024
Ended Jun 30, 2024
Aug 13, 2024After market close–$-0.60–
Q1 FY2024
Ended Mar 31, 2024
May 14, 2024After market close–$-0.76–
Q4 FY2023
Ended Dec 31, 2023
Mar 21, 2024After market close–––

Press releases

Announcements Alto Neuroscience filed with the SEC